



The Terry Fox Research Institute
L'Institut de recherche Terry Fox

Terry Fox Research Institute

Inaugural Scientific Meeting May 22-24, 2009

Program

WF= Waterfront Foyer

AB= Ballroom AB

C= Ballroom C

TBD= To be advised

Note: Room Location changes made May 21

Friday, May 22

Time	Activity	Duration	Location
1200 hrs	Registration and Poster Set Up		WF/AB
1300	Welcome /Opening Dr. Victor Ling	15 mins	C
1315-1445	Plenary I – Chair: Dr. Anne-Marie Mes-Masson	110mins	C
1315	Dr. Keith Humphries: Cell fate control of normal and malignant stem cells	30 mins	
1345	Dr. Bruno Gagnon & Dr. Imed Gallouzi: Towards an understanding of the Anorexia Cachexia Syndrome – linking molecular mechanisms with novel treatment options	30 mins	
1415	Dr. Michael Pollak: Clinical relevance of signaling pathways between insulin/IGF-1 receptors and protein translation machinery	30 mins	
1445	Dr. Pnina Brodt: Use of the IGF-Trap as a therapeutic agent	20 mins	
1505-1605	Break/Refreshments & Poster Session (Attended)	60 mins	WF/AB
1605-1745	Plenary II – Chair: Dr. Philip Branton	110 min	C
1605	Dr. Andras Nagy: Genetic analysis of signalling pathways for vascular development and tumour angiogenesis	30 mins	
1635	Dr. Joseph Connors: Biology of cancer: Insights from genomic analyses of lymphoid neoplasms	30 mins	
1705	Dr. Nizar Bahlis: Predicting benefit and improving outcomes of high dose therapy and autologous stem cell transplantation for myeloma patients through tissue array based classification.	30 mins	
1735	Dr. Yvan Guindon: In search of novel nucleoside analog anti-cancer agents	20 mins	
1830 - 2030	Buffet (Cash Bar) & Opening Poster Session	120 mins	AB
2030 – 2200	Poster Viewing (Late Session)	90 mins	AB

Saturday, May 23

0700	Breakfast		WF
0800 – 1000	Plenary III – Chair: Dr. Jerome Yates	120 mins	C
0800	Dr. Stephen Lam: Early detection of lung cancer – A Pan-Canadian study	30 mins	
0830	Dr. Stuart Foster: Medical imaging for cancer	30 mins	
0900	Dr. Richard Hill: Hypoxia in tumours: clinical and experimental studies	30 mins	
0930	Dr. Anne-Marie Mes-Masson: Canadian Ovarian Cancer Research Consortium: A Pan-Canadian Biomarker Initiative	10 mins	
0940	Dr. Peter Watson: Breast Cancer Biomarkers of Therapeutic Response Network: A Pan-Canadian Biomarker Initiative	10 mins	
0950	Dr. Fred Saad: Prostate Cancer Biomarker Network: A Pan-Canadian Biomarker Initiative	10 mins	
1000-1100	Refreshments & Posters (III) (Attended)	60 mins	WF/AB
1100 - 1230	Breakout Sessions (To be confirmed)	90 mins	TBA
1230-1400	Lunch & Posters (IV)	90 mins	WF
1400-1600	Plenary IV – Chair: Dr. David Parkinson	120 mins	C
1400	<i>Reports from Breakout Sessions</i>	30 mins	
1430	Dr. William Muller: Preclinical models and therapeutic targets for metastatic breast disease	30 mins	
1500	Dr. Kim Chi: A Phase II clinical trial of OGX-427 for prostate cancer	30 mins	
1530	Dr. Rob Rottapel: Ontario Cancer Institute: OICR/TFRI Selective Therapies Program	30 mins	
1600-1630	Break/Refreshments	30 mins	WF
1630-1800	Plenary V – Chair: Dr. Clayton Smith	90 mins	C
1630	Dr. John Bell: The Canadian Oncolytic Virus Consortium	30 mins	
1700	Dr. Jonathan Bramson: The Cancer Immunotherapy Program	30 mins	
1730	Dr. Dawn Waterhouse: Clinical translation of novel anti-cancer agent Irinophore C™ as a treatment for colorectal cancer	30 mins	
1900	Banquet	120 mins	AB

Sunday, May 24

0600 hrs	Early Run with Darrell Fox (departs 6:15 a.m.)		WF
0700	Breakfast		
0800-0930	Breakout Sessions (To be confirmed)	90 mins	TBA
0915	Refreshments Provided		WF
0930-1215	Plenary VI – Chair: Peter Forsyth	165 mins	C
0930	<i>Reports from Breakout Sessions</i>	15 mins	
0945	Dr. Christopher Paige: Molecular biology of hemopoietic progression and function	30 mins	
1015	Dr. Paul Rennie: Terry Fox Foundation program on prostate cancer progression	30 mins	
1045	Dr. John Mercer: Nucleic acid-based cancer imaging biomarkers	20 mins	
1105	Dr. Mario Chevrette: Predicting radiotherapy and chemotherapy response	20 mins	
1125	Mr. David Lesniak: B1 integrin as a novel predictive biomarker and a target in HER-2 positive trastuzumab resistant women with breast cancer	20 mins	
1145	Dr. Donna Hogge: Development of diphtheria toxin fusion proteins as a therapy for acute myeloid leukemia	20 mins	
1205	Closing Remarks Dr. Victor Ling	10 mins	
1215	CLOSE		

UPDATED MAY 21, 2009